Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.52 |
| ▸ | MERTK | Q12866 | 12/20 | 0.52 |
| ▸ | AXL | P30530 | 9/20 | 0.52 |
| ▸ | MET | P08581 | 1/20 | 0.52 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.52 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | PTGES | O14684 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12629181 | 0.86 | P2RX7 (0.52) | P2RX7MERTKAXLMETTYRO3 | |
| SCHEMBL14534809 | 0.86 | MERTK (0.53) | P2RX7MERTKAXLMETTYRO3 | |
| SCHEMBL27701237 | 0.86 | KCNA5 (0.53) | P2RX7MERTKAXLMETTYRO3 | |
| SCHEMBL13302610 | 0.85 | MERTK (0.49) | P2RX7MERTKAXLMETTYRO3 | |
| SCHEMBL4075331 | 0.84 | P2RX7 (0.50) | P2RX7MERTKAXLMETTYRO3 | |
| SCHEMBL2064031 | 0.83 | KCNA5 (0.51) | P2RX7MERTKAXLMETTYRO3 | |
| SCHEMBL5645993 | 0.83 | KMT2A (0.54) | P2RX7MERTKAXLMETTYRO3 | |
| SCHEMBL5435734 | 0.83 | KMT2A (0.54) | P2RX7MERTKAXLMETTYRO3 | |
| SCHEMBL12734545 | 0.83 | KMT2A (0.54) | P2RX7MERTKAXLMETTYRO3 | |
| SCHEMBL12734553 | 0.81 | KCNA5 (0.53) | P2RX7MERTKAXLMETTYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144698-A1 | SUBSTITUTED AZETIDINONES | DAIAMED (US) | 2010-06-10 | — | — | US | disclosed |
| US-20090143351-A1 | SUBSTITUTED AZETIDINONES | DAIAMED (US) | 2009-06-04 | — | — | US | disclosed |
| US-7501404-B2 | Substituted azetidinones | DAIMED (US) | 2009-03-10 | — | — | US | disclosed |
| US-20070105832-A1 | Substituted azetidinones | Cadrenal Therapeutics, Inc. | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105832-A1 | Substituted azetidinones | F2R, CPA3, CFD | P2RX7 1767/4885MERTK 2474/4885AXL 2747/4885 |
| US-20100144698-A1 | SUBSTITUTED AZETIDINONES | F2R, CPA3, CFD | P2RX7 1767/4885MERTK 2474/4885AXL 2747/4885 |
| US-20090143351-A1 | SUBSTITUTED AZETIDINONES | F2R, CPA3, CFD | P2RX7 1767/4885MERTK 2474/4885AXL 2747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.